The key to more efficient risk–benefit analysis

5 key steps to improve literature screening workflows

Improving literature monitoring for safety signal detection can positively impact the whole life cycle of a drug. Besides the obvious potential for more efficient and compliant pharmacovigilance reporting, the insights can also translate into vastly better risk–benefit assessments.

The ever-increasing amount of scientific information presents a major challenge as methods need to be put in place to ensure it is reviewed in its entirety to confidently claim that all adverse drug reactions have been captured. If the literature databases used are not comprehensive and/or the search strings and literature management processes and workflows are not optimized, there is a risk of missing safety information.

This white paper takes a detailed look at five steps to follow in building an efficient and compliant strategy for monitoring the biomedical literature for adverse drug reactions and shows how users can apply Elsevier solutions to successfully achieve each step.

To access the complimentary white paper 'The key to more efficient risk–benefit analysis', please fill in the form below.